CKD Patients Living With Hyperkalemia-Diabetes on DWN NEPHRO | Dialysis World Nigeria - DWN
CKD Patients Living With Hyperkalemia-Diabetes on DWN NEPHRO
Date Posted: 09/Dec/2015   Deadline: 09/Dec/2015

Diabetes mellitus is associated with a significantly increased prevalence of hyperkalemia among patients with stage 3 chronic kidney disease (CKD), a new study found.

The study found that stage 4 CKD and ACE inhibitor use are major determinants of hyperkalemia occurrence in multivariate analysis.

Charalampos Loutradis, MD, of Aristotle University of Thessaloniki in Greece, and colleagues conducted a nested case-control study of 180 type 2 diabetic and 180 non-diabetic patients with CKD.

The prevalence of hyperkalemia—defined as a serum potassium level above 5 mEq/L—was higher in the diabetic than non-diabetic patients (27.2% vs. 20%), but the difference was not statistically significant. Among patients with stage 3 CKD, the difference in hyperkalemia prevalence between diabetic and non-diabetic patients was statistically significant (28.6% vs. 17.5%).

The researchers observe no statistically significant difference in hyperkalemia prevalence among patients with stages 2 and 4 CKD.

Stage 4 CKD and use of ACE inhibitors were associated with 4.5-fold and 2.2-fold increased odds of hyperkalemia, respectively.

Source: RenalUrology, DWN Africa.

Share this news with friends!!!
Like us on Facebook